Physician profile
Rocky Chavez
NPI 1013148535
$1,358.27
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $329 · 2023: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $182.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $211.53 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $204.19 | 2019 | |
| Novo Nordisk INC | $199.25 | 2019-2020 | |
| Nevro Corp. | $159.10 | 2023 | Senza |
| Horizon Therapeutics Plc | $125.00 | 2020 | |
| Abbvie INC. | $94.17 | 2019-2023 | Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $56.58 | 2019 | |
| Merck Sharp & Dohme LLC | $41.52 | 2019-2020 | |
| Amgen INC. | $38.25 | 2019-2020 | |
| Pfizer INC. | $34.13 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $28.78 | 2019 | |
| Allergan, INC. | $25.25 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $23.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.68 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $12.02 | 2019 | |
| Lilly USA, LLC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rocky Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.